Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25902683 | 0.87 | THRA (0.47) | KMT2AATMCES2HCRTR1HCRTR2 | |
| SCHEMBL26020578 | 0.86 | CES2 (0.43) | KMT2AATMCES2HSP90AB1HCRTR1 | |
| SCHEMBL7786308 | 0.83 | PTPN1 (0.47) | KMT2AATMCES2HCRTR1HCRTR2 | |
| SCHEMBL26056992 | 0.83 | CES2 (0.66) | CES2HSP90AB1THRATHRBALDH1A1 | |
| SCHEMBL28278609 | 0.81 | CES2 (0.42) | CES2HSP90AB1THRATHRB | |
| SCHEMBL26020575 | 0.81 | RAB9A (0.47) | KMT2ACES2HSP90AB1THRATHRB | |
| SCHEMBL14010461 | 0.81 | CES2 (0.42) | CES2HSP90AB1THRATHRBALDH1A1 | |
| SCHEMBL30133947 | 0.80 | KMT2A (0.49) | KMT2AATMCES2HCRTR1HCRTR2 | |
| SCHEMBL2074860 | 0.80 | KMT2A (0.49) | KMT2AATMCES2HCRTR1HCRTR2 | |
| SCHEMBL25902695 | 0.80 | CTNNB1 (0.43) | KMT2AATMCES2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840507-B2 | Process for the preparation of phenyl ketones | ARXADA AG (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11840507-B2 | Process for the preparation of phenyl ketones | ARXADA AG (CH) | 2023-12-12 | — | — | US | disclosed |
| US-20230242469-A1 | Process for the Preparation of Phenyl Ketones | ARXADA AG (CH) | 2023-08-03 | — | — | US | disclosed |
| US-20230242469-A1 | Process for the Preparation of Phenyl Ketones | ARXADA AG (CH) | 2023-08-03 | — | — | US | disclosed |
| EP-4174069-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-8367667-B2 | Pyrrole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026237-B2 | For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide | EXELIXIS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | EXELIXIS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301128-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | KMT2A 4657/4885ATM 3620/4885CES2 1539/4885 |
| US-20080234270-A1 | Pyrrole Derivatives As Pharmaceutical Agents | PRLHR, PTGDR, TACR1 | KMT2A 4657/4885ATM 3620/4885CES2 1539/4885 |
| US-20230242469-A1 | Process for the Preparation of Phenyl Ketones | PAH, PDK4, PKM | KMT2A 869/4885ATM 2506/4885CES2 401/4885 |
| US-11840507-B2 | Process for the preparation of phenyl ketones | PAH, PDK4, PKM | KMT2A 869/4885ATM 2506/4885CES2 401/4885 |
| US-20110144128-A1 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands | NCOA1, NCOA2, NCOA3 | KMT2A 1448/4885ATM 4423/4885CES2 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.